CKD-FIX: A Randomised, Controlled Trial Of Allopurinol In The Slowing Of Kidney Disease Progression
Funder
National Health and Medical Research Council
Funding Amount
$1,917,147.00
Summary
Chronic kidney disease (CKD) is a major public health problem affecting over 1.5 million Australians and is associated with increased risk of death, heart disease and progression to end-stage kidney disease (ESKD). Current treatments to slow progression to ESKD are limited. The CKD-FIX trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows CKD progression. This could lead to significant health and economic benefits.
Enhancing Erythropoietin Therapy In Ischaemia-reperfusion Injury Of Heart And Kidney
Funder
National Health and Medical Research Council
Funding Amount
$361,021.00
Summary
Heart attacks and kidney disease from a lack of blood flow are common causes of morbidity and have poor treatment options. Erythropoietin (epo) is a useful new treatment, but there remain some caveats to its use in humans: eg. it may cause excessive scarring during repair. Use of epo with an anti-inflammatory drug may decrease scarring and provide benefit to long-term health. We plan to carefully define the biomolecular pathways of injury and repair, to better plan this therapy for human use.
Modulating Inflammatory And Fibrogenic Pathways In Kidney Disease Using A Novel Antagonist Of Protease-Activated-Receptor-2
Funder
National Health and Medical Research Council
Funding Amount
$581,116.00
Summary
Chronic kidney disease (CKD) now affects 10% of adults in industrialised countries. Current treatments are largely ineffective. Thus developing better CKD treatments will have substantial public health benefit. Three well established and clinically relevant animal models of kidney disease will be used to test the ability of a new experimental anti-inflammatory drug, developed by members of this research team at The University of Queensland, to prevent or lessen the progression of CKD.
Chronic Kidney Disease Centre Of Research Excellence
Funder
National Health and Medical Research Council
Funding Amount
$2,606,487.00
Summary
The Chronic Kidney Disease Centre of Research Excellence (CKD.CRE) is an Australian first, dedicated to the improvement of CKD knowledge and management across the health care spectrum. With five research streams, the CKD.CRE will establish a national surveillance network, support improved detection in primary care, inform on renal supportive care and on rationalised resource utilisation. In addition, the CKD.CRE will conduct biomarker research and will establish Australia’s first CKD BioBank.
Rapidly giving intravenous fluid to prevent or treat shock (fluid resuscitation) is one of the commonest treatments given to critically ill patients. Current guidelines recommend crystalloid solutions but it is unknown whether any particular crystalloid is better than others. This trial will determine whether the use of one of two crystalloid fluids, saline or PlasmaLyte, reduces the risk of organ injuries, such as kidney failure, and improves patients chances of surviving critically illness.
I-HEART - Implementation Of HEArt Failure Guidelines In Regional AusTralia
Funder
National Health and Medical Research Council
Funding Amount
$1,266,173.00
Summary
Heart failure (HF) is a common disease of the heart with a high rehospitalisation and mortality rate. Regional HF patients rarely receive the full benefits of evidence-based care simply due to inaccessibility to a HF specialist team. This translational project will implement key recommendations from clinical guidelines in regional health services and improve access to specialist services. It has the potential to keep patients out of hospital and save lives.
Integration Of Risk Evaluation In Cardiovascular Disease Management Programs.
Funder
National Health and Medical Research Council
Funding Amount
$5,162,176.00
Summary
This study will determine the feasibility of a coordinated health care team approach to the treatment of cardiovascular disorders. It will examine a range of issues – who would most benefit from this approach, its value for money, the relative importance of health care services to consumers, and where to invest additional health funds. Built on strong collaborations between expert researchers in advanced diagnostic techniques, coordinated health care, community health care and health economics, ....This study will determine the feasibility of a coordinated health care team approach to the treatment of cardiovascular disorders. It will examine a range of issues – who would most benefit from this approach, its value for money, the relative importance of health care services to consumers, and where to invest additional health funds. Built on strong collaborations between expert researchers in advanced diagnostic techniques, coordinated health care, community health care and health economics, this provides a unique opportunity to benefit millions of Australians.Read moreRead less
SGLT2 inhibitors are new glucose-lowering agents for type 2 diabetes. They promote glucose loss into urine, which lowers blood glucose levels. However, little is known regarding the changes to kidney physiology when this system is manipulated with these drugs. There is evidence that SGLT2 inhibitors do not protect against kidney disease in diabetic mice, despite being an effective blood glucose-lowering agent. I aim to characterise the changes to kidney function upon SGLT2 blockade in diabetes.
Detection And Management Of Depression In General Practice Patients With Chronic Manifestations Of Ischaemic Heart Disea
Funder
National Health and Medical Research Council
Funding Amount
$499,797.00
Summary
This research will investigate the impact of ischemic heart disease on the prevalence and severity of patients with depression. This will be done via a 12 month general practice based program of 1) systematic screening for depression 2) informing general practitioners of best-practice guidelines for management of depression in these patients, and 3) providing the treating general practitioner with patient-specific, psychiatric advice.